- Office Hours
- Venture Creation Program
- YEI Innovation Fund
- Technology Commercialization Program
- Venture Creation Consultants
- VC Advisors
- Canaan-Yale Venture Fellowship
- Miller Prize
- Yale Innovation Seminar Series
- Venture Creation Liaisons
Team Profile: Ancera
Team Name: Ancera
Team Members: Arjun Ganesan (SOM 2012), Hur Koser (Associate Professor – Electrical Engineering)
Industry: Biotech / In Vitro-Diagnostics
Ancera is in the business of rapid cell separation and pathogen diagnostics. Our products use label- and labor-free methods to provide low-cost, high-throughput separation and pathogen diagnostics in under 10 minutes. Current methods of pathogen diagnostics take anywhere from 24-96 hours for diagnosis.
Arjun is a rising second year at the Yale School of Management. He is a serial entrepreneur and has been involved in businesses in the brand consulting, media and entertainment spaces. He is a part of the Emerging Entrepreneurs Program at Yale SOM and is currently collaborating with Yale Office of Cooperative Research (OCR) to license technology to commercialize this device. He also has a B.E. in Computer Science Engineering from Anna University, India.
Dr. Hur Koser
Dr. Koser obtained double B.S. degrees and a Ph.D. in Electrical Engineering and Physics from the Massachusetts Institute of Technology (MIT). He has received the NSF Career Award for his work on ferrofluid dynamics and was awarded a prestigious Junior Faculty Fellowship (awarded by Yale University) to expand his work on ferrofluids. He is also the recipient of the 2003 Yale Information Technology Systems (ITS) Instructional Innovation Award and the Moore Award for the development of a microfluidics-based teaching laboratory.
What Problems did you see that led you to develop Ancera?
Bacterial and fungal infections are the root cause of Severe Sepsis, the second largest cause of death in non-coronary ICU’s (750,000+ cases with an estimated 215,000 deaths per year). With every hour of delay in treatment corresponding to 7% increase in mortality rate, the cost of treating an ICU patient with severe sepsis is six times that of a patient without sepsis. Last year, the cost of treatment was approximately $17 Billion.
How is the Ancera Solution different?
While companies such as Roche, Abbot and Molzym have invested in polymerase chain reaction (PCR) based technology, most of their methods typically take approximately 8- 30 hours to detect the pathogens and can risk contamination to the blood. While typical blood culture systems remain the gold standard in diagnosis, they take approximately 3 to 7 days to diagnose pathogens.
Ancera has successfully been able to separate bacteria with 99.3% efficiency from whole blood, 94.9% purity and 96.5% yield in pre-optimized laboratory results. Under optimal working conditions we are hoping to detect less than 10CFU/ml of bacteria.